CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences
February 21 2018 - 7:30AM
CRISPR Therapeutics (NASDAQ:CRSP), a genome editing company
focused on creating transformative medicine for serious diseases,
today announced that members of its senior management team are
scheduled to present at four upcoming Investor Conferences.
2018 RBC Capital Markets Global Healthcare
Conference Date: Thursday, February 22, 2018
Presentation: 8:00-8:25 AM ETWebcast available under Investor
Relations tab at CRISPRTx.com
Barclays Global Healthcare
Conference Date: Tuesday, March 13, 2018
Presentation: 3:20-3:45 PM ET
Guggenheim
Conference on Disruptive Technologies in Immuno-Oncology
Date: March 27th, 2018
17th Annual Needham
Healthcare Conference Date: March 28th,
2018Presentation: 3:30 PM ET
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused
on developing transformative gene-based medicines for serious
diseases using its proprietary CRISPR/Cas9 gene-editing platform.
CRISPR/Cas9 is a revolutionary technology that allows for precise,
directed changes to genomic DNA. The company's multi-disciplinary
team of world-class researchers and drug developers is working to
translate this technology into breakthrough human therapeutics in a
number of serious diseases. Additionally, CRISPR
Therapeutics has established strategic collaborations
with Bayer AG and Vertex Pharmaceuticals to
develop CRISPR-based therapeutics in diseases with high unmet need.
The foundational CRISPR/Cas9 patent estate for human therapeutic
use was licensed from the company's scientific
founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics
AG is headquartered in Zug, Switzerland, with its
wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and
R&D operations based in Cambridge, Massachusetts. For more
information, please visit http://www.crisprtx.com.
MEDIA CONTACT: Jennifer Paganelli WCG on behalf of
CRISPR +1 347-658-8290 jpaganelli@wcgworld.com
INVESTOR CONTACT: Chris Erdman +1
617.307.7227 chris.erdman@crisprtx.comChris Brinzey Westwicke
Partners for CRISPR +1
339-970-2843 chris.brinzey@westwicke.com
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Apr 2024 to May 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From May 2023 to May 2024